Reslizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Reslizumab and local guidelines before prescribing.
Biologic (anti-IL-5)
Mechanism
Anti-IL-5 monoclonal antibody (IV).
Uses
Severe eosinophilic asthma.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Anaphylaxis (rare), myalgia, raised CK.
Interactions
Few.
Contraindications and cautions
Active parasitic infection
Monitoring
Asthma control
Pregnancy and breastfeeding
Limited data
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Intravenous weight-based infusion.
More from the textbook: uses, cautions and other points
- Mepolizumab , reslizumab | IL-5 (eosinophil growth and survival) | Severe eosinophilic asthma; mepolizumab also for EGPA and some nasal polyps
Respiratory: Anatomy, Physiology and Pharmacology - Mepolizumab , reslizumab (anti-IL-5) and benralizumab (anti-IL-5 receptor): Severe eosinophilic asthma.
Respiratory: Airways Disease - Biologics (asthma) | Omalizumab (anti-IgE), mepolizumab, reslizumab, benralizumab (IL-5 pathway), dupilumab (IL-4/13), tezepelumab (TSLP) - specialist, NICE criteria.
Respiratory: Airways Disease - IL-5 / IL-5 receptor | Mepolizumab, reslizumab; benralizumab | Severe eosinophilic asthma, EGPA, hypereosinophilic syndrome | Parasitic infection (treat helminths first)
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology
Where it is discussed in the book
- Respiratory: Anatomy, Physiology and Pharmacology (1 mention)
- Respiratory: Airways Disease (2 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- Integrated respiratory chapter (2 mentions)